A carregar...

Immunotherapy for Type 1 Diabetes – targeting the innate immune system

Moran et al report two trials of antagonism of the pro-inflammatory cytokine, IL-1, assessing the monoclonal antibody canakinumab and the IL-1 antagonist, anakinra in new-onset Type 1 Diabetes (T1D). The studies both showed that, although relatively safe, there was no efficacy in terms of halting de...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wong, F. Susan, Wen, Li
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4048745/
https://ncbi.nlm.nih.gov/pubmed/23732280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrendo.2013.103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!